Trial · NCT04589130
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 27 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Changes in eating behaviours from baseline as assessed by Yale Food Addiction Scale (YFAS) (self administered questionnaire) | Week 0 to Week 28 and Week 52 | To determine the effect of Contrave compared to placebo on eating behaviours, in a post behaviour modification program population. |
| Secondary | Changes in food cravings from baseline as assessed by Favourite Food Craving Scale (FFCS) (self administered questionnaire) | Week 0 to Week 28 and Week 52 | To determine the effect of Contrave compared to placebo on food cravings, in a post behaviour modification program population. |
| Secondary | Changes in depression from baseline as assessed by Patient Health Questionnaire 9 (PHQ-9) (self administered questionnaire) | Week 0 to Week 28 and Week 52 | To determine the effect of Contrave compared to placebo on depression and depressive problems, in a post behaviour modification program population. |
| Secondary | Changes in risk of suicidality from baseline as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 0 to Week 12, Week 28 and Week 52 | To determine the effect of Contrave compared to placebo on risk of suicidality, in a post behaviour modification program population. |
| Other | Incidences of adverse events (AE) | Week 0 to Week 52 | To determine the safety profile of Contrave in a weight loss maintenance setting in a post behaviour modification population. |
| Other | Incidences of serious adverse events (SAE) | Week 0 to Week 52 | To determine the safety profile of Contrave in a weight loss maintenance setting in a post behaviour modification population. |
| Other | Number of participants discontinuing investigational product due to AE/SAEs | Week 0 to Week 52 | To determine the tolerability profile of Contrave in a weight loss maintenance setting in a post behaviour modification program population. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04589130/registered?page=2